This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Clinical Trials
DRAGON study
This study will explore the safety and efficacy of oral tinlarebant tablets as compared to oral placebo tablets, in slowing down disease progression, or the changes to the retina, in people with Stargardt disease.
Overview
This study will explore the safety and efficacy of oral tinlarebant tablets as compared to oral placebo tablets, in slowing down disease progression, or the changes to the retina, in people with Stargardt disease. This study is involving people aged 12 to 20 years, before significant vision loss and retinal degeneration has occurred.
This study will follow up participants for 2 years and measure the size and pattern of disease using various retinal imaging modalities. Additionally, a range of visual function assessments will be performed.
- Principal Investigator
Dr Thomas Edwards
This study will explore the safety and efficacy of oral tinlarebant tablets as compared to oral placebo tablets, in slowing down disease progression, or the changes to the retina, in people with Stargardt disease. This study is involving people aged 12 to 20 years, before significant vision loss and retinal degeneration has occurred.
This study will follow up participants for 2 years and measure the size and pattern of disease using various retinal imaging modalities. Additionally, a range of visual function assessments will be performed.
- Principal Investigator
Learn more
View this study at ClinicalTrials.gov
This database listing provides more detailed information about this study.